Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Allergic Rhinitis Stories

2009-09-16 12:14:00

ANTONY, France, September 16 /PRNewswire-FirstCall/ -- Stallergenes S.A. has announced the first results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen and concerning the development of a sublingual immunotherapy tablet containing the recombinant allergen of this pollen, rBet v 1. This study is the first ever to use a recombinant allergen as an active substance. To Stallergenes' knowledge, the use of a recombinant protein in dry...

2009-09-11 17:11:03

The runny nose and post-nasal drip of allergic rhinitis, or hay fever, puts a damper on sex and sleep, U.S. researchers found. Dr. Michael Benninger, chairman of the Head and Neck Institute at the Cleveland Clinic in Ohio who was the study author, said the study assessed the impact of allergic rhinitis on sexual function, sleep and fatigue. The researchers used the Rhinosinusitis Disability Index, a quality-of-life scale, in several groups of people -- a group of normal subjects, patients...

2009-08-26 07:30:00

NAPLES, Fla., Aug. 26 /PRNewswire/ -- Most people might think of nettle as simply a common and aggressive weed that can sting and cause skin irritation. But nettle has also been used for hundreds of years to treat seasonal allergies and other inflammatory diseases, although the precise nature of its anti-inflammatory effect was unknown. Now, scientists with HerbalScience have identified specific bioactives in nettle leaf extracts that inhibit in vitro receptors and enzymes known to be key...

2009-04-16 06:00:00

First Selective TLR8 Agonist to Advance for Treatment of Allergy SAN DIEGO, April 16 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and inflammatory diseases, announced today that it has initiated a Phase I clinical trial of VTX-1463, a selective intranasal TLR8 agonist for the treatment of allergic rhinitis. The objectives of this trial will be to...

2008-11-10 18:00:05

Research findings presented at the 2008 American College of Allergy, Asthma and Immunology (ACAAI) Scientific Meeting revealed a significant cost savings associated with allergy immunotherapy (IT) in children with allergic rhinitis (AR). This pioneering study, supported by Greer, was summarized during an oral presentation by Cheryl Hankin, Ph.D., President and Chief Scientific Officer of BioMedEcon and principal investigator of the study, at the ACAAI meeting, held Nov. 6-11 in Seattle, Wash....

2008-11-07 09:00:05

Morria Biopharmaceuticals, a developer of anti-inflammatory drugs, has announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The nasal allergen challenge study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared with both placebo (arm 1) and an intranasal steroid Rhinocort (as a positive control, arm 2)....

2008-11-06 11:17:34

LONDON and NEW YORK, Nov. 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared...

2008-10-29 12:00:07

LONDON, Oct. 29 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs, announced today the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort(R) as the steroid comparator arm. A secondary efficacy...

2008-09-23 03:00:27

BRIDGEWATER, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the U.S. Food and Drug Administration (FDA) has approved Nasacort AQ Nasal Spray (triamcinolone acetonide) for children aged 2-5 years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively...

2008-08-27 03:00:24

By Anonymous Doctors usually tell parents of a newborn not to introduce solid foods until the baby is at least four to six months old, ostensibly to lessen the chances that the infant will develop atopic diseases - asthma, allergic rhinitis (runny nose), eczema, and food and inhalant sensitization - later on in life. In a recent study that was published in the January 2008 issue of Pediatrics, researchers in Germany looked into whether delaying the introduction of solids past four or six...